Phase 3 placebo-controlled study of telotristat etiprate in carcinoid syndrome

Phase 3, randomised, double-blind trial of telotristat ethyl in Carcinoid Syndrome (CS) and apudoma (NET) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Change from baseline in number of daily bowel movements over 12 weeks, Incidence of treatment-emergent adverse events and 1 more. Started Feb 2015; status: active, not recruiting.